Old Web
English
Sign In
Acemap
>
authorDetail
>
P.E. Reimitz
P.E. Reimitz
Daiichi Sankyo
Medicine
Edoxaban
Cardiology
Atrial fibrillation
Internal medicine
4
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry
2021
European Heart Journal
R. De Caterina
R Wang
L. Shi
Ladislav Pecen
X. Ye
P.E. Reimitz
Cathy Chen
Martin Unverdorben
Robert P. Giugliano
Show All
Source
Cite
Save
Citations (0)
Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program
2021
European Heart Journal
Leon Dinshaw
Cathy Chen
R. De Caterina
W Jiang
Y.H. Kim
Yukihiro Koretsune
Doralisa Morrone
Ladislav Pecen
P.E. Reimitz
C.C Wang
Takanori Yamashita
Martin Unverdorben
Paulus Kirchhof
Show All
Source
Cite
Save
Citations (0)
Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF
2021
Europace
Doralisa Morrone
Martin Unverdorben
C-L Chen
L Dinshaw
W Jiang
Y.H. Kim
P. Kirchhof
Yukihiro Koretsune
Ladislav Pecen
P.E. Reimitz
C.C Wang
Takeshi Yamashita
R. De Caterina
Show All
Source
Cite
Save
Citations (0)
Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program
2021
Europace
L Dinshaw
Martin Unverdorben
C-L Chen
R. De Caterina
W Jiang
Y.H. Kim
Yukihiro Koretsune
Doralisa Morrone
Ladislav Pecen
P.E. Reimitz
C.C Wang
Takeshi Yamashita
P. Kirchhof
Show All
Source
Cite
Save
Citations (0)
1